OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback